Veterans with apnea-hypopnea index scores implying no sleep apnea or severe sleep apnea had higher all-cause mortality rates ...

Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine ...

Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

An 8-week weight loss and lifestyle intervention improved vitamin D levels up to 6 months after treatment among men with OSA and high BMI.

In a prior Australian Phase 2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index (AHI ... including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder.

Obstructive Sleep Apnea (OSA) is a common sleep disorder in children characterized by repeated interruptions in breathing during sleep due to the obstruction of the upper airway. This condition ...

The ΔCO, which is the gap between the presleep and postsleep venous CO levels, was positively correlated with AHI and with hypoxia ... related to hypoxia during sleep in OSA patients.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Frequency of moderate physical activity was associated with improved negative emotional memory consolidation among older adults.

SURMOUNT-OSA trials: Zepbound reduced apnea events by 62.8%, improving sleep apnea outcomes ... a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea. Research shows that it considerably improves the level of AHI in patients with ...